{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:26:59Z","timestamp":1790908019142,"version":"4.1.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the association between midphase hyperfluorescent plaques (MPHP) with subretinal fluid (SRF) dynamics in central serous chorioretinopathy (CSCR) and to assess response across different therapeutic modalities using a validated quantitative approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective, multicenter study in patients with CSCR. All patients underwent baseline and follow-up indocyanine green angiography and enhanced depth imaging optical coherence tomography. MPHP were measured on midphase indocyanine green angiography images, and changes in MPHP number and area were correlated with various imaging parameters. Response of MPHP to different treatment modalities were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study included 96 eyes of 60 patients, 50 men (83.33%) and 10 women (16.67%) with CSCR. Over a median follow-up of 31 months, significant reductions were observed in central macular thickness (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003), SRF height (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), subfoveal choroidal thickness (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), and MPHP area (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), while MPHP number and best recorded visual acuity remained stable. Photodynamic therapy (PDT) and laser induced greater SRF reduction (\u2212125.0 \u00b1 143.2\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m and \u2212123.8 \u00b1 139.5\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m) and MPHP area decrease (\u22124.14 \u00b1 6.13 mm\n                      <jats:sup>2<\/jats:sup>\n                      and \u22121.75 \u00b1 2.98 mm\n                      <jats:sup>2<\/jats:sup>\n                      , respectively) compared with Eplerenone and observation (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). Multivariable analysis confirmed PDT as the strongest independent predictor of MPHP area regression (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.001), while baseline SRF height and symptom duration predicted final SRF height (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>MPHP represent a frequent and dynamic angiographic feature in CSCR, closely associated with disease activity. PDT significantly reduced MPHP area and promoted SRF resolution, supporting its role as an effective treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004913","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:03:10Z","timestamp":1782129790000},"page":"1799-1807","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["MIDPHASE HYPERFLUORESCENT PLAQUES AS A BIOMARKER OF DISEASE ACTIVITY IN CENTRAL SEROUS CHORIORETINOPATHY"],"prefix":"10.1097","volume":"46","author":[{"given":"Giulia","family":"Gregori","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Polytechnic University of Marche, Eye Clinic, Ancona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niroj K.","family":"Sahoo","sequence":"additional","affiliation":[{"name":"UPMC Eye Centre, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasiq","family":"Hasan","sequence":"additional","affiliation":[{"name":"UPMC Eye Centre, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lupidi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Polytechnic University of Marche, Eye Clinic, Ancona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Saju","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Zhou","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihteh","family":"Wu","sequence":"additional","affiliation":[{"name":"Asociados de Macula Vitreo y Retina de Costa Rica, San Jos\u00e9, Costa Rica."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[{"name":"UPMC Eye Centre, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Macula Society International CSCR Research Network (MICRoN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260922","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ajo.2009.11.017","article-title":"Central serous chorioretinopathy: a personal perspective","volume":"149","author":"Yannuzzi","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41433-019-0381-7","article-title":"Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options","volume":"33","author":"Sartini","year":"2019","journal-title":"Eye"},{"key":"R3-20260922","first-page":"14","article-title":"Pachychoroid disease","volume":"33","author":"Cheung","year":"2019","journal-title":"Eye Lond Engl"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"100973","DOI":"10.1016\/j.preteyeres.2021.100973","article-title":"Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders","volume":"86","author":"Spaide","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.3390\/jcm10194525","article-title":"Mid-phase hyperfluorescent plaques seen on indocyanine green angiography in patients with central serous chorioretinopathy","volume":"10","author":"Bousquet","year":"2021","journal-title":"J Clin Med"},{"key":"R7-20260922","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00006982-199919060-00005","article-title":"Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy","volume":"19","author":"Iida","year":"1999","journal-title":"Retina"},{"key":"R8-20260922","doi-asserted-by":"crossref","first-page":"100901","DOI":"10.1016\/j.xops.2025.100901","article-title":"Association between choroidal vascular hyperpermeability and vortex vein anastomoses in central serous chorioretinopathy","volume":"6","author":"Miyara","year":"2026","journal-title":"Ophthalmol Sci"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/jcm11061706","article-title":"Clinical characteristics and multimodal imaging findings of central serous chorioretinopathy in women versus men","volume":"11","author":"Bousquet","year":"2022","journal-title":"J Clin Med"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00417-023-05985-7","article-title":"Ten-year follow-up and sequential evaluation of multifocal retinal pigment epithelium abnormalities in central serous chorioretinopathy","volume":"261","author":"Sahoo","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-20260922","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.oret.2025.04.005","article-title":"Clinical characteristics and progression of pachychoroid macular atrophy in central serous chorioretinopathy","volume":"9","author":"Hasan","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"R12-20260922","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1177\/11206721211055018","article-title":"One year outcome and predictors of treatment outcome in central serous chorioretinopathy: multimodal imaging based analysis","volume":"32","author":"Arora","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R13-20260922","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41433-021-01885-4","article-title":"Imaging characteristics of bilateral CSCR cases: 12 months follow up","volume":"37","author":"Singh","year":"2023","journal-title":"Eye"},{"key":"R14-20260922","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/00006982-200312000-00002","article-title":"Photodynamic therapy for chronic central serous chorioretinopathy","volume":"23","author":"Cardillo Piccolino","year":"2003","journal-title":"Retina"},{"key":"R15-20260922","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.3390\/jcm13195729","article-title":"Settings and clinical applications of subthreshold micropulse laser therapy: a review","volume":"13","author":"Sorrentino","year":"2024","journal-title":"J Clin Med"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40942-023-00500-w","article-title":"Real-world practice patterns of eplerenone use for central serous chorioretinopathy","volume":"9","author":"Venkatesh","year":"2023","journal-title":"Int J Retina Vitreous"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:00:42Z","timestamp":1790096442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004913"}},"subtitle":["Clinical Course and Treatment Response \u2013 MICRoN Report Number Ten"],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004913","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}